Excelra Acquires BISC Global, Creating an International Bioinformatics Powerhouse With an Industry-Leading Platform and Service Offering.
19.4.2023 16:00:00 EEST | Business Wire | Press release
Excelra, a leading life science data and digital solutions provider, has acquired BISC Global, a bioinformatics and data analytics consulting company with offices across Europe and the USA. The acquisition creates an international powerhouse in consulting-led bioinformatics, with expertise in artificial intelligence, machine learning, and omics and next-generation sequencing data analysis.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230419005464/en/
Excelra is a trusted partner to the world's top pharmaceutical and biotechnology companies, providing data, insight, and R&D technology services. Its interdisciplinary teams of biocurators, bioinformaticians, data scientists, and engineers deliver harmonized data, optimized analysis pipelines, and advanced applications to accelerate drug discovery and development.
BISC Global is a consulting-led platform and service provider specializing in bioinformatics, biostatistics, artificial intelligence, and machine learning. It provides data analysis, pipeline development, cloud computing, and data visualization services. It also offers next-generation platforms such as the Online Pipeline Platform (OP2), which supports streamlined analysis of bulk RNA-seq, single-cell RNA-seq, somatic variant calling, and germline variant calling data; and ImmunoRaptor, an analysis platform that makes it easy for researchers to manage and analyze immune repertoire sequencing data.
BISC Global's leadership believes the acquisition will expand bioinformatics innovation and benefit customers of both organizations. "We are excited about the acquisition by Excelra and are confident that the synergies between our two organizations will enable our consultants to provide best-in-class bioinformatics services to the life science industry," said BISC Global CEO Maarten Braspenning.
Excelra CEO Anandbir Singh Brar said, "The acquisition of BISC Global is a strategic move that enhances our capabilities and expands our reach in the bioinformatics field. The combined entity will be amongst the industry leaders in bioinformatics platforms and services, and will have a major positive impact on the future of bioinformatics and the life science industry."
The acquisition creates a game-changing bioinformatics powerhouse, committed to driving innovation at the intersection of science and technology.
About Excelra
Excelra provides data, insight, and R&D technology services to the world's top pharmaceutical and biotech companies. From offices in Boston, Utrecht, London, and Hyderabad, Excelra's 1000+ domain experts operate at the intersection of science and technology to empower life science innovation and accelerate drug discovery and development. Excelra provides integrated solutions from data to insight. It starts by structuring and harmonizing diverse scientific data sets. Then it builds custom R&D data engineering, cloud infrastructure solutions, tailored computational models, and optimized analysis pipelines to lead the way to groundbreaking discoveries. For more information, visit excelra.com.
About BISC Global
Founded in 2017, BISC Global has grown to be a Top 10 Bioinformatics Consulting and Services Firm, supporting the world's leading pharmaceutical and biotech companies. BISC provides data analytics, custom tool/pipeline development, and cloud solutions delivered on-site or remotely. It has a global workforce of expert consultants, operating from offices in Ghent, Belgium; Basel, Switzerland; Amsterdam, The Netherlands; Boston, MA; and San Francisco, CA. BISC supports analysis across multiple domains, including machine learning (data mining, pattern recognition, image analysis, (un)supervised learning, neural networks, deep learning, etc.), bioinformatics (single-cell transcriptomics, metabolomics, metagenomics, epigenomics, etc.), and statistics (experimental design, mathematic modeling, signal-to-noise enhancement, and independent data cross-validation). For more information, visit biscglobal.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230419005464/en/
Contact information
Jigesh Shah
Jigesh.shah@excelra.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ushio Industry & Entertainment Appoints Takuya Matsumoto as President & CEO and Outlines Strategic Direction for the Next Phase20.4.2026 13:32:00 EEST | Press release
Ushio Industry & Entertainment (Ushio INE GmbH) announces the appointment of Takuya Matsumoto as President and Chief Executive Officer, marking a key milestone in the evolution of the business and its integration within the Ushio Group. With more than 20 years of experience across sales, new business development, and global operations, Takuya Matsumoto brings deep industry expertise and a strong leadership track record within Ushio. Most recently, he served as General Manager of the Global Business Unit, where he played a pivotal role in advancing global growth initiatives. A Clear Vision: A strong heritage with a forward-looking vision focused on innovation, operational excellence, and customer value Under Takuya Matsumoto’s leadership, Ushio INE will continue to build on its strong legacy while advancing its mission to deliver high-performance, high-quality lighting solutions across industrial and entertainment markets worldwide. “Our mission is to continuously deliver essential ligh
Ushio Industry & Entertainment Appoints Takuya Matsumoto as President & CEO and Outlines Strategic Direction for the Next Phase20.4.2026 13:32:00 EEST | Press release
Ushio Industry & Entertainment (Ushio INE GmbH) announces the appointment of Takuya Matsumoto as President and Chief Executive Officer, marking a key milestone in the evolution of the business and its integration within the Ushio Group. With more than 20 years of experience across sales, new business development, and global operations, Takuya Matsumoto brings deep industry expertise and a strong leadership track record within Ushio. Most recently, he served as General Manager of the Global Business Unit, where he played a pivotal role in advancing global growth initiatives. A Clear Vision: A strong heritage with a forward-looking vision focused on innovation, operational excellence, and customer value Under Takuya Matsumoto’s leadership, Ushio INE will continue to build on its strong legacy while advancing its mission to deliver high-performance, high-quality lighting solutions across industrial and entertainment markets worldwide. “Our mission is to continuously deliver essential ligh
Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 202620.4.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that CEO Kabir Nath will participate in a panel entitled “Clinical Risk, Regulatory Reality and the Path to Scale” at the Needham Virtual Psychedelics Forum on April 27, 2026, at 11am-12pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable response
Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 202620.4.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that CEO Kabir Nath will participate in a panel entitled “Clinical Risk, Regulatory Reality and the Path to Scale” at the Needham Virtual Psychedelics Forum on April 27, 2026, at 11am-12pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable response
PPG invests in testing line for radiation-curable coatings at Marly, France20.4.2026 12:00:00 EEST | Press release
PPG (NYSE: PPG) today announced the installation of an advanced testing line for radiation-curable coatings at its R&D Center of Excellence in Marly, France. The line can test multiple curing technologies, including infrared (IR), ultraviolet (LED, excimer and arc lamps), and electron beam (EB). This investment allows the company to accurately replicate customer production conditions, helping accelerate development cycles and reduce the number of customer trials. Unlike conventional thermal curing, radiation curing requires less energy because it operates at or near ambient temperature. This reduction in energy demand can significantly lower carbon emissions by 65%*, with further gains possible when powered by renewable energy sources. In addition, UV- and EB-curable systems typically use 100% solids formulations with no solvents, reducing or eliminating volatile organic compound emissions. Beyond sustainability advantages, UV- and EB-based technologies deliver significant productivity
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
